Le Lézard
Classified in: Health, Science and technology

Global Pharma and Biotech Dealmaking Royalty Rate Trends Report 2021 - ResearchAndMarkets.com


The "Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010-2021" report has been added to ResearchAndMarkets.com's offering.

The Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010-2021 report is your one-stop source for providing real-deal information on hundreds of transactions, including the technology licensed, royalty rates, license fees, upfront and milestone payments.

This report provides details of the latest partnering deals which disclose a royalty rate, announced in the pharmaceutical, biotechnology and diagnostic sectors. The report provides details of partnering deals disclosing royalty rates from 2010 to 2021.

The report provides an overview of how and why companies enter partnering deals where a royalty is payable upon commercialization of the compound or technology.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all partnering deals announced since 2010 where a quantitative royalty rate has been disclosed, as recorded in the deals and alliances database. Each deal record and royalty disclosure is available in further detail via a link to online copy of the deal including actual contract document, where available, as submitted to the Securities Exchange Commission by companies and their partners.

The report includes deals announced by hundreds of life science companies including big pharma such as Abbott, Abbvie, Actavis, Amgen, Astellas, AstraZeneca, Baxter, Bayer, Biogen Idec, BMS, Celgene, Eisai, Eli Lilly, Gilead, GSK, J&J, Kyowa Hakko, Merck, Mitsubishi, Mylan, Novartis, Pfizer, Roche, Sanofi, Shire, Takeda, Teva, and Valeant, amongst many others.

The report also includes numerous table and figures that illustrate the trends in royalty rates in pharma and biotech deal making since 2010. In conclusion, this report provides everything a prospective dealmaker needs to know about royalty rates in the pharma and biotech sector.

Key benefits

Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010 - 2021 provides the reader with the following key benefits:

Available deals and contracts are listed by:

Analyzing actual contract agreements allows assessment of the following:

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

1.1. What are royalties?

1.2. History of royalty rates

1.3. Royalties in pharma and biotech

1.4. Royalties versus revenue share

1.5. Overview of the report

Chapter 2 - An overview of pharma and biotech royalty rates

2.1. Trends in royalty rates 2010-2021

2.2. Royalty rate disclosure in pharma and biotech

2.3. How do revenue shares figure?

2.4. A review of recent literature

2.5. Royalty rates in the future

Chapter 3 - Average royalty rates for pharma and biotech partnering

3.1. Royalty rates in early stage deals

3.2. Royalty rates by stage of development

3.3. Royalty rates by therapy area

Chapter 4 - The royalty clause in pharma and biotech deals

4.1. Partnering agreement structure

4.2. Structure of a typical royalty clause

4.3. Example royalty clauses

4.3.1. Case study 1: Merck Serono-Opexa Therapeutics

4.3.2. Case study 2: Aradigm - Grifols

4.3.3. Case study 3: Forect Laboratories - Trevena

4.3.4. Case study 4: Sage Therapeutics - University of California

Chapter 5 - Companies actively disclosing royalty rates

5.1. 25 most active companies in disclosing royalty rates

5.2. Top partnering deals by royalty rate

5.3. Top partnering deals by royalty rate

Chapter 6 - Royalty rate contract directory

Explore royalty rates within the deal contract document to gain greater insight

Appendices

Appendix 1 - Royalty rates in deals - by company A-Z

Appendix 2 - Royalty rates in deals - by therapy area

Appendix 3 - Royalty rates in deals - by stage of development at signing

Appendix 4 - Royalty rates in deals - by technology type

Appendix 5 - Royalty rate references

Appendix 6 - Resources

Appendix 7 - Deal type definitions

Appendix 8 - Example royalty rate deal contract document

For more information about this report visit https://www.researchandmarkets.com/r/ft4cyo


These press releases may also interest you

at 16:45
Ryan, a leading global tax services and software provider, is challenging a new rule issued by the Federal Trade Commission (FTC) that outlaws non-compete employment agreements. The Firm's lawsuit in federal court in Texas is the first challenge to...

at 16:37
Reveal Technology, Inc. (Reveal) is proud to share that they have received a selection notification from the US Air Force AFVentures Program for a $33.6M Strategic Funding Increase (STRATFI)....

at 16:35
Evolus, Inc. , a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its first quarter 2024 financial results on Tuesday, May 7, 2024, after the U.S. financial markets...

at 16:33
The ProLift Rigging Company, a leading provider of solutions-based industrial construction services in North America, announced, today, it has been honored with two Safety Awards from The Specialized Carriers & Rigging Association (SC&RA) --The Crane...

at 16:30
Veralto (the "Company"), a global leader in essential water and product quality solutions dedicated to Safeguarding the World's Most Vital Resourcestm announced results for the first quarter ended March 29, 2024....

at 16:30
Everyone plays a role in reducing the plastic waste that chokes our landfills and the plastic pollution that litters our streets, shorelines, waterways, and even our food supply. Improving how plastics are made, used, and managed can help protect...



News published on and distributed by: